PFS was defined as time from treatment initiation of systemic 1-L therapy start date to documented date of tumor progression or date of death. Disease progression (PD) was defined as greater than equal to (>=) 20% increase in sum of diameters of the target lesions taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study) or unequivocal progression in non-target lesions or appearance of 1 or more new lesions. Analysis was performed by Kaplan-Meier method.

Analysis population included all eligible participants whose data was retrieved and observed retrospectively in this study.

PFS was defined as time from treatment initiation of systemic 1-L therapy start date to documented date of tumor progression or date of death. Disease progression (PD) was defined as greater than equal to (>=) 20% increase in sum of diameters of the target lesions taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study) or unequivocal progression in non-target lesions or appearance of 1 or more new lesions. PFS rate was percentage of participants with PFS.

Analysis population included all eligible participants whose data was retrieved and observed retrospectively in this study.

PFS was defined as time from treatment initiation of systemic 1-L therapy start date to documented date of tumor progression or date of death. Disease progression (PD) was defined as greater than equal to (>=) 20% increase in sum of diameters of the target lesions taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study) or unequivocal progression in non-target lesions or appearance of 1 or more new lesions. PFS rate was percentage of participants with PFS.

Analysis population included all eligible participants whose data was retrieved and observed retrospectively in this study.

PFS was defined as time from treatment initiation of systemic 1-L therapy start date to documented date of tumor progression or date of death. Disease progression (PD) was defined as greater than equal to (>=) 20% increase in sum of diameters of the target lesions taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study) or unequivocal progression in non-target lesions or appearance of 1 or more new lesions. PFS rate was percentage of participants with PFS.

Analysis population included all eligible participants whose data was retrieved and observed retrospectively in this study.

PFS was defined as time from treatment initiation of systemic 1-L therapy start date to documented date of tumor progression or date of death. Disease progression (PD) was defined as greater than equal to (>=) 20% increase in sum of diameters of the target lesions taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study) or unequivocal progression in non-target lesions or appearance of 1 or more new lesions. PFS rate was percentage of participants with PFS.

Analysis population included all eligible participants whose data was retrieved and observed retrospectively in this study.

OS was defined as time from treatment initiation of systemic 1-L therapy to date of death due to any cause or last day of contact. Analysis was performed by Kaplan-Meier method.

Analysis population included all eligible participants whose data was retrieved and observed retrospectively in this study.

OS was defined as time from treatment initiation of systemic 1-L therapy to date of death due to any cause or last day of contact. OS rate was measured as percentage of participants alive at specified time points.

Analysis population included all eligible participants whose data was retrieved and observed retrospectively in this study.

Number of participants were classified according to different drug groups prescribed: Immune checkpoint inhibitors + Tyrosine kinase inhibitor (ICI +TKI), ICI+ICI, TKI alone and ICI alone.

Analysis population included all eligible participants whose data was retrieved and observed retrospectively in this study.

Number of participants were classified according to different drug regimen therapies prescribed: pembrolizumab + axitinib, nivolumab + ipilimumab, sunitinib, nivolumab, cabozantinib, tivozanib, pembrolizumab, pazopanib, axitinib and avelumab + axitinib.

Analysis population included all eligible participants whose data was retrieved and observed retrospectively in this study.

Best overall response was documented as the best response documented in the participant record. CR was defined as complete resolution of all visible disease as per the treating physician's opinion. PR was defined as partial reduction in size of visible disease in some or all areas without any areas of increase in visible disease. Disease progression (PD) was defined as greater than equal to (>=) 20% increase in sum of diameters of the target lesions taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study) or unequivocal progression in non-target lesions or appearance of 1 or more new lesions. Stable disease was defined as not qualifying for CR, PR, PD. In this outcome measure percentage of participants with best responses are recorded.

Analysis population included all eligible participants whose data was retrieved and observed retrospectively in this study.

DOR was defined as time from first disease response (CR/PR) to tumor progression among participants with a documented response and also had a documented date of response. CR was defined as complete resolution of all visible disease as per the treating physician's opinion. PR was defined as partial reduction in size of visible disease in some or all areas without any areas of increase in visible disease. Analysis was performed by Kaplan-Meier method.

Analysis population included all eligible participants whose data was retrieved and observed retrospectively in this study. Here "Number of Participants Analyzed" signifies participants evaluable for this outcome measure.

TTP was defined as time from start of treatment of systemic 1 L therapy up to tumor progression without including deaths. Disease progression (PD) was defined as greater than equal to (>=) 20% increase in sum of diameters of the target lesions taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study) or unequivocal progression in non-target lesions or appearance of 1 or more new lesions. Analysis was performed by Kaplan-Meier method.

Analysis population included all eligible participants whose data was retrieved and observed retrospectively in this study.

TTNT was defined as time from last systemic 1 L therapy administered up to start of next therapy among those participants who completed 1L therapy. Analysis was performed by Kaplan-Meier method.

Analysis population included all eligible participants whose data was retrieved and observed retrospectively in this study. Here "Number of Participants Analyzed" signifies participants evaluable for this outcome measure.

A dose modification was defined as dose reduction of 1 or all drugs. Number of participants with dose modifications or with an interim/permanent discontinuation of one or all drugs of a therapy were reported in this outcome measure.

Analysis population included all eligible participants whose data was retrieved and observed retrospectively in this study.

A dose modification was defined as dose reduction of 1 or all drugs. Number of participants with dose modification of one or two drugs but continuing therapy were reported in this outcome measure.

Analysis population included all eligible participants whose data was retrieved and observed retrospectively in this study. Here "Number of Participants Analyzed" signifies participants evaluable for this outcome measure.

Number of participants with discontinuation of one or two drugs were reported in this outcome measure.

Analysis population included all eligible participants whose data was retrieved and observed retrospectively in this study. Here "Number of Participants Analyzed" signifies participants evaluable for this outcome measure.

Number of participants continuing therapy after temporary/permanent discontinuation of single drugs are reported in this outcome measure.

Analysis population included all eligible participants whose data was retrieved and observed retrospectively in this study. Here "Number of Participants Analyzed" signifies participants evaluable for this outcome measure.